Healthcare Industry News:  Provectus Pharmaceuticals 

Biopharmaceuticals Dermatology

 News Release - January 14, 2008

Provectus Pharmaceuticals Receives Patent Allowance in India

Intellectual Property Protection for PH-10, Lead Dermatology Agent

KNOXVILLE, Tenn.--(HSMN NewsFeed)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received allowance of its patent application in India covering its lead dermatology agent, PH-10, along with a number of related agents. The pending patent covers topical products for treatment of skin diseases such as psoriasis and eczema. Additionally, a range of active compounds are protected, each related to the active ingredient in PH-10.

“Coming on the heels of our recent patent in India for PV-10, our lead oncology agent, this pending patent for PH-10 is yet another major milestone for us since it secures access to a market that represents roughly one-fifth of the world’s population,” said Craig Dees, PhD, CEO of Provectus. “Moreover, since the Indian pharmaceutical industry is becoming an important player in the global marketplace, this patent will afford Provectus the right of ownership for products sold or made in India.”

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting clinical trials of their proprietary drugs PV-10 as a therapy for melanoma and breast cancer, and PH-10 as a topical treatment for severe psoriasis. The Company recently commenced Phase 2 clinical testing of PV-10 for melanoma and received orphan drug designation from the FDA for melanoma. Initial Phase 1 clinical trial objectives for PV-10 for breast cancer were completed in April 2006, but the trial has been extended to more properly determine optimal dosing. Additionally, the Company has begun Phase 2 of clinical testing of its topical product PH-10 for psoriasis. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company’s website at www.pvct.com or contact the Investor Relations Group via the information provided below.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.


Source: Provectus Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.